TY - JOUR
T1 - Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA
AU - Lehmann-Werman, Roni
AU - Magenheim, Judith
AU - Moss, Joshua
AU - Neiman, Daniel
AU - Abraham, Ofri
AU - Piyanzin, Sheina
AU - Zemmour, Hai
AU - Fox, Ilana
AU - Dor, Talya
AU - Grompe, Markus
AU - Landesberg, Giora
AU - Loza, Bao Li
AU - Shaked, Abraham
AU - Olthoff, Kim
AU - Glaser, Benjamin
AU - Shemer, Ruth
AU - Dor, Yuval
PY - 2018/6/21
Y1 - 2018/6/21
N2 - Liver damage is typically inferred from serum measurements of cytoplasmic liver enzymes. DNA molecules released from dying hepatocytes are an alternative biomarker, unexplored so far, potentially allowing for quantitative assessment of liver cell death. Here we describe a method for detecting acute hepatocyte death, based on quantification of circulating, cell-free DNA (cfDNA) fragments carrying hepatocyte-specific methylation patterns. We identified 3 genomic loci that are unmethylated specifically in hepatocytes, and used bisulfite conversion, PCR, and massively parallel sequencing to quantify the concentration of hepatocyte-derived DNA in mixed samples. Healthy donors had, on average, 30 hepatocyte genomes/ml plasma, reflective of basal cell turnover in the liver. We identified elevations of hepatocyte cfDNA in patients shortly after liver transplantation, during acute rejection of an established liver transplant, and also in healthy individuals after partial hepatectomy. Furthermore, patients with sepsis had high levels of hepatocyte cfDNA, which correlated with levels of liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Duchenne muscular dystrophy patients, in which elevated AST and ALT derive from damaged muscle rather than liver, did not have elevated hepatocyte cfDNA. We conclude that measurements of hepatocyte-derived cfDNA can provide specific and sensitive information on hepatocyte death, for monitoring human liver dynamics, disease, and toxicity.
AB - Liver damage is typically inferred from serum measurements of cytoplasmic liver enzymes. DNA molecules released from dying hepatocytes are an alternative biomarker, unexplored so far, potentially allowing for quantitative assessment of liver cell death. Here we describe a method for detecting acute hepatocyte death, based on quantification of circulating, cell-free DNA (cfDNA) fragments carrying hepatocyte-specific methylation patterns. We identified 3 genomic loci that are unmethylated specifically in hepatocytes, and used bisulfite conversion, PCR, and massively parallel sequencing to quantify the concentration of hepatocyte-derived DNA in mixed samples. Healthy donors had, on average, 30 hepatocyte genomes/ml plasma, reflective of basal cell turnover in the liver. We identified elevations of hepatocyte cfDNA in patients shortly after liver transplantation, during acute rejection of an established liver transplant, and also in healthy individuals after partial hepatectomy. Furthermore, patients with sepsis had high levels of hepatocyte cfDNA, which correlated with levels of liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Duchenne muscular dystrophy patients, in which elevated AST and ALT derive from damaged muscle rather than liver, did not have elevated hepatocyte cfDNA. We conclude that measurements of hepatocyte-derived cfDNA can provide specific and sensitive information on hepatocyte death, for monitoring human liver dynamics, disease, and toxicity.
KW - Diagnostics
KW - Epigenetics
KW - Hepatology
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=85055261576&partnerID=8YFLogxK
U2 - https://doi.org/10.1172/jci.insight.120687
DO - https://doi.org/10.1172/jci.insight.120687
M3 - مقالة
C2 - 29925683
SN - 0256-2804
VL - 3
JO - JCI Insight
JF - JCI Insight
IS - 12
ER -